T-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for T-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating CAR.70, engineered IL-15-transduced cord blood-derived natural killer (NK) cells, in combination with…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Universal 4SCAR7U Targeting CD7-positive Malignancies [Phase 1]
A Phase 1 trial evaluating Universal 4SCAR7U, a CD7-targeting therapy from Shenzhen Geno-Immune Medical Institute, is currently recruiting. …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) [Phase 2]
Phase 2 study of WU-CART-007, an allogeneic anti-CD7 CAR-T therapy, for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma, is c…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL [Phase 3]
Phase 3 clinical trial update evaluating the combination of a PD-1 inhibitor with venetoclax and the CAG regimen for relapsed/refractory T-c…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma [Phase 1]
This Phase 1 study investigates a quadruplet regimen of venetoclax, dexamethasone, bortezomib, and daratumumab in adolescents and young adul…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL [Phase 2]
This is a Phase 2 precision medicine trial for patients with relapsed or refractory T cell acute lymphoblastic leukemia.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma [Phase 1]
Phase 1 clinical trial evaluating targeted immunotherapy after myeloablative conditioning and allogeneic stem cell transplant in children an…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial evaluating DA-EPOCH chemotherapy with or without Rituximab plus recombinant Erwinia asparaginase (JZP458) for newly d…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL [Phase 2]
A Phase 2 clinical trial evaluating daratumumab for chemotherapy-refractory minimal residual disease in T-cell acute lymphoblastic leukemia …
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) [Phase 1]
Phase 1 clinical trial of CD123-directed T-cell therapy for acute myeloid leukemia and related hematologic diseases is currently recruiting …
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients [Phase 2]
A Phase 2 clinical trial is evaluating venetoclax in combination with azacitidine as initial therapy for newly diagnosed T-cell acute lympho…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: U69-CART-Cells For R/R T-ALL [Phase 1]
Phase 1 clinical trial of U69-CART-Cells for relapsed/refractory T-lymphoblastic leukemia/lymphoma, currently recruiting.
-
CLINICAL_TRIALS withdrawal · 2026-03-17Clinical Trial Update: A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma [Phase 1, Phase 2]
A Phase 1/2 CAR-T trial for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma has been withdrawn.
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL [EARLY_Phase 1]
This update outlines an early-phase (Phase 1) clinical trial evaluating CD7 CAR-T therapy for newly diagnosed high-risk T lymphoblastic lymp…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) [Phase 2]
This Phase 2 clinical trial is evaluating a combination of calaspargase pegol-mknl, decitabine, and venetoclax in pediatric, adolescent, and…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). [Phase 1, Phase 2]
The document updates on an ongoing clinical trial of GYA01 (CART84) for relapsed/refractory acute myeloid leukemia and T-cell acute lymphobl…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma [Phase 3]
Ongoing Phase 3 clinical trial evaluating levocarnitine to protect the liver from chemotherapy in children with acute lymphoblastic leukemia…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL [Phase 1]
OC-1 therapy is being studied in a Phase 1 trial to assess safety and efficacy in relapsed/refractory T-cell acute lymphoblastic leukemia an…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies [Phase 1, Phase 2]
An update on an ongoing Phase 1/2 clinical trial evaluating CD5-targeted CAR T cells for relapsed or refractory T-cell malignancies, includi…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting [Phase 2]
This clinical trial update describes a Phase 2 study of venetoclax plus azacitidine for acute myeloid leukemia in the post-transplant settin…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia [Phase 2]
Phase II trial evaluating the combination of ponatinib with mini-hyper CVD chemotherapy and venetoclax in relapsed or refractory T-cell acut…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program [Phase 2]
A Phase 2 clinical trial evaluates daratumumab for very high-risk T-cell acute lymphoblastic leukemia under the ALL National Treatment Progr…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells [Phase 1]
A Phase 1 clinical trial update on an allogeneic CD7-targeted CAR-T cell therapy for high-risk T-cell malignancies (T-cell acute lymphoblast…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) [Phase 2]
A Phase 2 pediatric trial is evaluating adding dasatinib or venetoclax to initial therapy to improve responses in newly diagnosed T-cell acu…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of venetoclax and vincristine in adults with relapsed or refractory B- or T-cell acute lymphoblas…